Professor Ashrafian is a Managing Partner at SV Health Investors and co-founded Alchemab in 2019. Alongside Alchemab he has founded six other SV companies; Cellinta, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics and Imbria.
Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.
Outside of SV, following completion of his cardiology training, Houman was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and head of Experimental Therapeutics at the University of Oxford. Additionally, Houman is co-founder and Chairman of Weatherden, a boutique clinical development company.